Archives
Cisapride (R 51619): Evidence-Bounded Overview
Cisapride is presented by APExBIO as a research-use compound with two scientifically important annotations: activity as a nonselective 5-HT4 receptor agonist and inhibition of the human ether-à-go-go-related gene (hERG) potassium channel. Related web material also uses the designation R 51619, although the linked product record identifies the material as Cisapride, catalog number B1198. The product description supports a documented identity and a plausible cardiac research context, but it does not substitute for an identity-matched pharmacology or electrophysiology study.
Documented identity and scientific context
According to the APExBIO Cisapride product page, the compound is 4-amino-5-chloro-N-((3S,4R)-1-(3-(4-fluorophenoxy)propyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide, with the molecular formula C23H29ClFN3O4 and a reported molecular weight of 465.95. The page describes it as a solid and reports supplier quality-control documentation including HPLC, NMR, and MSDS materials, together with a stated purity above 99.7%.
These details are product-level identity and quality claims, not evidence that a particular biological preparation contained the material or that the stated purity predicts a specific assay response. The same page reports solvent-solubility and stability information, but those physicochemical statements should be interpreted as handling metadata rather than as evidence of receptor activity, hERG inhibition, or performance in a cardiac model.
Documented mechanism and measurement meaning
5-HT4 receptor signaling
The supplier characterizes Cisapride as a nonselective 5-HT4 receptor agonist. In conceptual terms, receptor agonism is an upstream pharmacological event: it describes interaction with a receptor and the initiation of receptor-linked signaling. A downstream cellular readout—such as a change in excitability, contractile behavior, or another signaling-associated phenotype—would not by itself prove that 5-HT4 engagement caused the observation. The product description supplies no affinity values, concentration-response parameters, receptor-panel data, or pathway-specific measurements with which to quantify that claim.
hERG channel inhibition and electrophysiology
APExBIO also describes Cisapride as a potent inhibitor of the hERG potassium channel. hERG is relevant to cardiac electrophysiology because its current contributes to ventricular repolarization. Consequently, hERG inhibition is mechanistically connected to electrophysiological measurements that reflect repolarization and rhythm. That connection explains why the product is positioned for cardiac electrophysiology research and cardiac arrhythmia research.
However, a change in a downstream electrophysiological readout is not equivalent to a direct measurement of hERG binding or current inhibition. It may reflect several levels of biology, including channel activity, cellular compensatory processes, other ion channels, cell-state effects, or assay-specific measurement behavior. The supplied material does not report a direct current measurement, a quantitative potency estimate, a comparison compound, or an observed arrhythmic phenotype for this product.
Why the dual annotation matters
The stated 5-HT4 receptor agonism and hERG channel inhibition should be treated as distinct pharmacological claims. Their coexistence does not establish that one mechanism produces the other, nor does it establish which mechanism dominates a particular readout. This distinction matters when interpreting a phenotype: a signal associated with the 5-HT4 receptor signaling pathway and a signal associated with altered repolarization may arise through different causal routes, even when measured in the same biological system.
Interpretation of the supplied properties and scope
| Claim or context | What the supplied source reports | What can reasonably be inferred |
|---|---|---|
| Identity | The APExBIO page gives a chemical name, formula, molecular weight, physical form, and catalog number. | These are documented product descriptors. They do not independently establish batch identity or biological equivalence across suppliers. |
| Quality metadata | The page states purity above 99.7% and lists HPLC, NMR, and MSDS documentation. | This indicates the type of quality information supplied by the vendor; it is not a published, identity-matched efficacy or potency result. |
| 5-HT4 pharmacology | The product is described as a nonselective 5-HT4 receptor agonist. | This supports a hypothesis about receptor-linked signaling, but no quantitative receptor pharmacology is supplied. |
| hERG pharmacology | The product is described as a potent hERG potassium-channel inhibitor. | This provides a mechanistic rationale for cardiac electrophysiology research, but no direct current, potency, or exposure-response data are provided. |
| Cardiac safety context | The product description links hERG inhibition with investigations of electrophysiology and drug-induced arrhythmias. | The relationship is biologically plausible as a research question; it does not demonstrate a specific risk magnitude, predictive value, or clinical outcome. |
The relevant measurement principle is therefore hierarchical. A target annotation is an upstream mechanistic premise; channel-current or receptor-assay measurements are closer to target-level evidence; and cellular rhythm or contractility phenotypes are downstream observations. Each level answers a different question. Without data linking the levels in the same study, it would be inappropriate to treat a downstream phenotype as proof of a particular molecular mechanism.
Evidence availability and specific boundaries
No identity-matched research paper is available in the supplied record. Accordingly, there are no supported sample sizes, effect estimates, uncertainty intervals, experimental comparators, biological models, or reported outcomes that can be attributed here to Cisapride or R 51619. The supplier page supports documentation of the product’s stated identity and mechanism claims, but not independent validation of those claims.
One related article, “Cisapride, hERG Signaling, and iPSC Cardiotoxicity”, is relevant only as contextual material. Its supplied summary explicitly states that it does not establish that Cisapride was tested in the cited screen or that an in-vitro signal predicts clinical risk on its own. It therefore cannot be used as evidence of product performance, nor can the broader iPSC-cardiotoxicity measurement context be transferred directly to this catalog item.
Similarly, general discussion of high-content imaging, iPSC-derived cardiomyocytes, or predictive modeling would establish properties of a measurement context rather than demonstrate that Cisapride was used, detected, or validated in that context. The supplied related pages do not provide a documented product-specific comparison, outcome dataset, or independent replication. They should therefore be treated as secondary, unverified context rather than as primary evidence.
Concise factual synthesis
APExBIO documents Cisapride (B1198) as a compound with the stated molecular identity and two prominent pharmacological annotations: nonselective 5-HT4 receptor agonism and hERG potassium-channel inhibition. Those annotations make the compound conceptually relevant to serotonergic signaling, cardiac electrophysiology research, hERG channel inhibition studies, and cardiac arrhythmia research. The mechanistic interpretation is strongest at the level of a research premise: 5-HT4 activity concerns receptor-linked signaling, whereas hERG inhibition concerns a repolarization-related ion-channel mechanism.
The evidence boundary is equally important. The supplied material contains no matched study demonstrating target engagement, no quantitative pharmacology, and no product-specific cardiac outcome. Thus, Cisapride’s documented product identity and stated mechanism can frame research questions, but they do not establish assay performance, predictive cardiotoxicity, or clinical significance.